Clinical Trial Detail

NCT ID NCT03989362
Title Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer (EMERGE)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Jounce Therapeutics, Inc.
Indications

lung non-small cell carcinoma

transitional cell carcinoma

Therapies

Ipilimumab + Vopratelimab

Age Groups: senior adult

No variant requirements are available.